R B Pedley - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

R B Pedley

Showing results (71-80 of 73) with videos related to

Pageof 8

Sort By:

You have reached the last page of results.This site can display upto 73 results.

British Journal of Cancer|May 24, 2007

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour modelsE El-Emir, J L J Dearling, A Huhalov, et al.

European Journal of Cancer (Oxford, England : 1990)|October 16, 2007

From laboratory to Phase I/II cancer trials with recombinant biotherapeuticsB Tolner, L Smith, T Hillyer, et al.

British Journal of Cancer|May 3, 2002

Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical phase I/II studyJ L Casey, M P Napier, D J King, et al.

Pageof 8

Search research articles

Showing results (71-80 of 73) with videos related to

Sort By:

Pageof 8

You have reached the last page of results.This site can display upto 73 results.

British Journal of Cancer|May 24, 2007

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour modelsE El-Emir, J L J Dearling, A Huhalov, et al.

European Journal of Cancer (Oxford, England : 1990)|October 16, 2007

From laboratory to Phase I/II cancer trials with recombinant biotherapeuticsB Tolner, L Smith, T Hillyer, et al.

British Journal of Cancer|May 3, 2002

Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical phase I/II studyJ L Casey, M P Napier, D J King, et al.

Pageof 8